{"name":"CytoDyn","slug":"cytodyn","ticker":"CYDY","exchange":"OTC","domain":"cytodyn.com","description":"CytoDyn is a clinical-stage biotechnology company focused on developing leronlimab, a CCR5 antagonist, for various therapeutic areas, including HIV, cancer, and inflammatory diseases. The company has a pipeline of products, including leronlimab, which has shown promising results in clinical trials. CytoDyn is a relatively small company with a limited market presence compared to larger biotechnology companies.","hq":"Vancouver, WA","founded":0,"employees":"","ceo":"Cyrus Arman, PhD","sector":"Clinical-Stage Biotechnology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$75M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":7240000,"netIncome":3745000,"cash":18047000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Leronlimab patent cliff ($0.0B at risk)","drug":"Leronlimab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Optimized Background Regimen","genericName":"Optimized Background Regimen","slug":"optimized-background-regimen","indication":"HIV-1 infection (as background regimen component in clinical trials)","status":"phase_3"}]}],"pipeline":[{"name":"Optimized Background Regimen","genericName":"Optimized Background Regimen","slug":"optimized-background-regimen","phase":"phase_3","mechanism":"An optimized antiretroviral background regimen designed to enhance the efficacy of leronlimab (a CCR5 antagonist) in HIV treatment.","indications":["HIV-1 infection (as background regimen component in clinical trials)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"CytoDyn Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"CytoDyn reported its financial results for the fourth quarter and full year 2023, with a net loss of $13.4 million and $54.6 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"CytoDyn Announces $10 Million Private Placement","summary":"CytoDyn announced a $10 million private placement of its common stock to raise capital for its operations.","drugName":"","sentiment":"positive"},{"date":"2023-09-26","type":"trial","headline":"CytoDyn Announces Positive Top-Line Results from Phase 2b Clinical Trial of Leronlimab in COVID-19 Patients","summary":"CytoDyn announced positive top-line results from its Phase 2b clinical trial of leronlimab in COVID-19 patients, showing a significant reduction in mortality and hospitalization rates.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-08","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRTFBMEZYZ2JyRk1jUktpUjdpX1R1aEJWdFoyZndxYk5mM3BmekEyWnZJQVhXUmVrOVBuODI1ZUI3a25EckJhNGZGY1EyTV9xVnZvLU9qclgwdmdDRzkxRjJBcmVFYlhMMlM5RmF0QlNRcUlWS3Znd0x4VjcwRFdGTkRLYm9ITE8tbjhUUXpCdmEzUFBFRWs5Q0l6Wl8wN0hMUVAwNXpjVU5rTlFLbjMxc25vbzhPRFRJT1JCTmxUUm8?oc=5","date":"2026-03-05","type":"pipeline","source":"Stock Titan","summary":"$17.5M bet on cancer drug leronlimab for tough breast, colon tumors - Stock Titan","headline":"$17.5M bet on cancer drug leronlimab for tough breast, colon tumors","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE0tdmFscEtJbmtkNFF3azg4dHh6YUMwZ1FBZDJxR0ZYUkJvRmR3bUVEUFhxQUxaNk5YV0RieEI1RmhTUXd2Rm9TZlFHUDBZaVpFR3dTWlhB?oc=5","date":"2026-02-14","type":"pipeline","source":"Stock Titan","summary":"CYDY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan","headline":"CYDY Financials: Income Statement, Balance Sheet & Cash Flow","sentiment":"neutral"},{"date":"2026-01-09","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNeDBJQ2VUTjQydzZ1bHA5dW1mOG1fX3FjR1dFc3EyaVpxWVloVmxCQlZOdmR6YUJzOWpUdkFwNW9DQkxZZnJ2LTJ6WlFZczJORURPeG93VjlFV2YzQzVyYmZKZVBxZm5KV0ZHcElGUElYa3ljRU92Sk4yR1BzcENPXzg4MmdrRkJWd09iTNIBlAFBVV95cUxNYWtkTzRCR3JrMXQtcFNNd2syRGRObDVlOTBfenZMYnJfVFFYaTg4N2lwNHNsSHVVQ0ltZFBYc1pJWWpzZVRyVXJDQU15ZEVfeFotN1VmTzRYUldRbnBtejNHWlJkZVdEREE4V1JrMjR1eHRXWTI3WXRXUGoxQk1uODRuR19aTmdBRWFOd1JBeW1wXzBf?oc=5","date":"2025-07-17","type":"pipeline","source":"Law Street Media","summary":"Some Research Into Short-Seller Culper Research - Law Street Media","headline":"Some Research Into Short-Seller Culper Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOSWFlNkJUYVhrTU43MEh4Qm9VeFlsQWxFOEt2YTlIXzNNMnRyM1Ria3BlVTlvQjk1cElfczFxSkR4cWNlWFI2NkcxSDB4d3lCZVdPcVQzbnhheW1LTUhPOHRPeUdsQlI3c3Nra1cySGRnUzlhTDBWeUdmMEp1U3JFNFo0R195Y2JvekYyVVpTbE9VVGlpWi1KQ05VeURwV09PRXRtNkk4U0w2amVFd0hXVklpeXNmTE1k?oc=5","date":"2025-05-06","type":"pipeline","source":"CytoDyn Inc.","summary":"CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn Inc.","headline":"CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPSWh0LVRTMFU3dHBKNzBHU2Fkc1BGY21LNVJKRk1BeEFGM2JGaTI0aUVWUXFWeXNyaFo2dGtVZmNMTGh2Z1FRSFg1Q1VFQ3RBbGJqdVlsQVVYaUZBMHI1bllqSE1Vemd6RkNHVW8wZTdzeFVJaTFZajgteDVPdlB4SlhKLVowYmpDWkxBQzdFVGhhaWpK?oc=5","date":"2024-10-30","type":"pipeline","source":"CytoDyn Inc.","summary":"CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories - CytoDyn Inc.","headline":"CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies wi","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2021-07-24","type":"pipeline","source":"cnbc.com","summary":"Large shareholder group calls for a board overhaul at pharma company CytoDyn - cnbc.com","headline":"Large shareholder group calls for a board overhaul at pharma company CytoDyn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE1IMXdERVdwZFJUR3JYdFh5NEVycmJFVkRod2pfTFZMSmZ1NEZxaXFaZ2JjSkdlRUZiWm9LalQzb29GQ2VqUzdJQnZhdWpLQUpvUWRTUlowUDZGR3lLMGpEMnFiVXU?oc=5","date":"2021-04-29","type":"pipeline","source":"Market Realist","summary":"CYDY Stock Might See Better Days in 2021 and Rise to $10 - Market Realist","headline":"CYDY Stock Might See Better Days in 2021 and Rise to $10","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPLW5sUHFwY29OVXROd2JnaW5MM3phOVV5Y0VVQmlUQTAyQU5Ubjdka1V2cVV5am8xOURSOFhSOWVOVnh6cUhIZENFU1VOT1B4NmdMMmpwaERhWjh3TFViOUhxb29JazluNGZnbjZoT0RDMFl0SFA2Wjk2dGR5T3Y0SmdLTlVYSFQyT1E?oc=5","date":"2021-04-08","type":"pipeline","source":"Pharmaceutical Technology","summary":"CytoDyn and Biomm enter leronlimab supply agreement - Pharmaceutical Technology","headline":"CytoDyn and Biomm enter leronlimab supply agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE9DZE5CN3pLR2M0UlBVdVY3YVhER0cxQ3A5b2RieFgwWmZwT2E1R2RsZE9zdUJvZkxVbmZNaC1uMEg2UmNBYWlDTlljanIyQkh4RmdteDBfRXU?oc=5","date":"2017-07-21","type":"pipeline","source":"TradingView","summary":"CYDY Stock Price and Chart — OTC:CYDY - TradingView","headline":"CYDY Stock Price and Chart — OTC:CYDY","sentiment":"neutral"}],"patents":[{"drugName":"Leronlimab","drugSlug":"leronlimab","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","ViiV Healthcare","Merck & Co."],"therapeuticFocus":["HIV","Cancer","Inflammatory Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2023-05-31","revenueHistory":[{"value":0,"period":"2023-05-31"},{"value":266000,"period":"2022-05-31"},{"value":266000,"period":"2022-05-31"},{"value":0,"period":"2021-05-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":7240000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":3745000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":18047000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}